Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 12, 2008, Pages 2058-2059

  Cardoso, Fatima ^a   Saghatchian, Mahasti ^b   Thompson, Alastair ^c  

^a JULES BORDET INSTITUTE   (Belgium)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; TUMOR MARKER;

BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DECISION MAKING; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MEDICAL RESEARCH; MEDICAL SOCIETY; PHYSICIAN; PRIORITY JOURNAL; VALIDATION STUDY; BREAST TUMOR; FEMALE; NOTE; PRACTICE GUIDELINE;

BREAST NEOPLASMS; FEMALE; GUIDELINES AS TOPIC; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 42949125386     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.6638     Document Type: Letter

References (16)

1. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
2. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996
3. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
4. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
5. van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
6. van de Vijver MJ, He YD, van 't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
7. Buyse M, Loi S, van't Veer L, et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183-1192, 2006
8. Goldhirsch A, Wood WC, Gelber RD, at al: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144, 2007
9. Colozza M, Azambuja E, Cardoso F, et al: Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann Oncol 16:1723-1739, 2005
10. Press MF, Mass RD, Zhou JY, et al: Association of topoisomerase II alpha (TOP2A) gene amplification with responsiveness to anthracycline-containing chemotherapy among women with metastatic breast cancer entered in Herceptin H0648g pivotal clinical trial. J Clin Oncol 23:847s, 2005 (suppl; abstr 9543)
11. Di Leo A, Gancberg D, Larsimont D, et al: HER2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107-1116, 2002
12. Tanner MM, Isola J, Wiklund T, et al: Topoisomerase II alpha gene amplification predicts favorable treatment response of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER2/neu amplified breast cancer: Results from the randomized Scandinavian Breast Group Trial 9401. J Clin Oncol 24:1-9, 2006
13. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIalpha amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol, 23:7483-7490, 2005
14. Coon JS, Marcus E, Gupta-Burt S, et al: Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8:1061-1067, 2002
15. O'Malley FP, Chia S, Tu D, et al: Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). J Clin Oncol 24:533, 2006
16. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006 (abstr 52)